Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 3, 2006, Pages 290-296

  Rich, Michael L ^a,b,c   Socci, A R ^a,b,d   Mitnick, C D ^c,d   Nardell, E A ^a,c   Becerra, M C ^a,b,c,d   Bonilla, C ^e   Bayona, J ^a,b,c,d   Seung, K J ^a,b   Furin, J ^a,b,c   Farmer, P E ^a,b,c,d   Mukherjee, J S ^a,b,c,d  

^a PARTNERS IN HEALTH   (United States)

^b SOCIOS EN SALUD   (Peru)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MINISTERIO DE SALUD   (Peru)

Author keywords

Drug resistance; Individualized; MDR TB; Retreatment; Standardized; Tuberculosis

Indexed keywords

ANISIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; PERU; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; INCIDENCE; MALE; PERU; RESEARCH DESIGN; RETREATMENT; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 33645221147     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Dye C, Espinal M A, Watt C J, Mbiaga C, Williams B G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2001; 185: 1197-1202.
2. Blower S M, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004; 10: 1111-1116.
3. World Health Organization. Treatment of Tuberculosis. Guidelines for National TB Programmes. 3rd ed. WHO/CDS/ TB/2003.313. Geneva, Switzerland: WHO, 2003.
4. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481.
5. Chan E D, Laurel V, Strand M J, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
6. Suarez P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
7. Van Deun A, Hamid Salim M A, Kumar Das A P, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.
8. Park, S K, Lee W C, Lee D H, et al. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8: 361-368.
9. Weyer K, Lancaster J, Van der Walt M, et al. DOTS-Plus for multidrug-resistant (MDR) tuberculosis in South Africa: results from the first cohort of patients treated with a standardized regimen under tuberculosis control program conditions. Int J Tuberc Lung Dis 2002; 6 (Suppl 1): S138.
10. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug resistant tuberculosis: treatment outcomes in six countries. JAMA 2000; 283: 2537-2545.
11. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
12. Fraser H S, Jazayeri D, Mitnick C D, Mukherjee J S, Bayona J. Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. Proc AMIA Symp 2002: 270-274.
13. Iseman M D, Huitt G A. Treatment of multidrug-resistant tuberculosis. In: Bastian I, Portaels F, eds. Multidrug-resistant tuberculosis. London, UK: Kluwer Academic Publishers, 2000.
14. Partners In Health. The PIH Guide to the Management of Multidrug-resistant Tuberculosis. Boston, MA: Partners In Health, 2003.
15. Saravia J C, Appleton S C, Rich M L, Sarria M, Bayona J, Becerra M C. Re-treatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 2005; 9: 421-429.
16. de March Ayuela P, Turell Guma J. Resultados obtenidos mediante regimenes de asociación con dos o tres drogas secundarias en el retratamiento del tuberculoso pulmonar crónico. Rev Clin Esp 1968; 109: 117-126.
17. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
18. Tuberculosis Research Center. Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy. Int J Tuberc Lung Dis 2001; 5: 40-45.
19. Quy H T W, Lan N T N, Borgdorff M W, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-636.
20. Rigouts L, Portaels F. DNA fingerprints of Mycobacterium tuberculosis do not change during the development of resistance to various anti-tuberculosis drugs. Tubercle Lung Dis 1994; 75: 160.
21. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 2004; 8: 31-38.
22. Jave O, Castilla T, Prado A, Asto T. Drug-susceptibility testing to antituberculous drugs in new patients who fail Category I regimen 2RHZE/4R2H2 (from Peru). Poster presented at the IUATLD Latin American Region Conference, Guayaquil, Ecuador, 24-27 October 2000.
23. Trebucq A, Anagonou S, Gninafon M, Lambregts K, Boulahbal F. Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to antituberculosis drugs in Benin after 12 years of short-course chemotherapy. Int J Tuberc Lung Dis 1999; 3: 466-470.
24. Kritski A L, Rodrigues de Jesus L S, Andrade M K, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997; 111: 1162-1167.
25. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 2004; 8: 31-38.
26. Tsukamura M, Toyama H, Mizuno S, Tsukamura S. Cross resistance relationship among capreomycin, kanamycin, viomycin and streptomycin resistances of M. tuberculosis. Kekkaku 1967; 42: 399-404.
27. Tsukamura M. Cross-resistance relationships between capreomycin, kanamycin and viomycin resistances in tubercle bacilli from patients. Amer Rev Respir Dis 1969; 99: 780-782.
28. Tsukamura M, Mizuno S. Cross-resistant relationships among the aminoglycoside antibiotics in Mycobacterium tuberculosis. J Gen Microbiol 1975; 88: 269-274.
29. Han L L, Sloutsky A, Canales R, et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly-observed empiric retreatment with standardized regimens. Int J Tuberc Lung Dis 2005; 9: 818-821.
30. Ministerio de Salud del Perú. 'Actualización en la atención de pacientes con tuberculosis multidrogorresistente (TB MDR).' Norma técnica 025-MINSA/DGSP-V.01, aprobado por la Resolución Ministerial 162-2005. Lima, Perú: Ministerio de Salud, 3 de marzo de 2005.